A research team at Sungkyunkwan University (SKKU) in South Korea, led by Professors In Ki Kim and Jong-Chan Park alongside Researcher Han-Jun Cho, published a study in the renowned journal ACS Nano. Their ultra-sensitive, real-time dopamine measurement technology based on ‘Organoid-on-a-chip’ marks a new milestone in precision medicine for Parkinson’s disease treatment.

This article provides a systematic overview of:

1. Pathological origins and medical differences between Parkinson’s disease and Alzheimer’s disease.
2. Latest medical frameworks for early diagnosis and treatment of Alzheimer’s disease.
3. Comprehensive investment value analysis from biomedical and medical device perspectives.

1. Two Giants of Brain Disorders: Comparing the Origins of Parkinson’s vs. Alzheimer’s

While both conditions are irreversible neurodegenerative diseases caused by neuronal loss in the brain, clear differences exist in their causative substances, primary affected regions, and symptom onset patterns.

• Parkinson’s Disease: Occurs when the dopamine-producing factory—the central switch of the motor circuit—is destroyed. Cognitive function is often preserved in the early stages, allowing patients to clearly recognize their own motor impairments.
• Alzheimer’s Disease: Caused by the gradual accumulation of metabolic protein waste (amyloid/tau) in the brain over decades, which slowly degrades the hippocampus and cerebral cortex, ultimately leading to loss of cognitive ability.

2. New Medical Framework for Early Alzheimer’s Diagnosis and Treatment

While past dementia treatment focused merely on post-symptom alleviation (Acetylcholinesterase inhibitors), the recent medical framework has shifted toward a fundamental diagnostic and therapeutic paradigm: Early Screening via Blood Biomarkers → Targeted Antibody Therapy → Ultra-fast MRI Monitoring.

[Step 1: Blood Biomarker Test] ➔ [Step 2: PET / Rapid MRI Precision Exam] ➔ [Step 3: Anti-Amyloid Antibody Dosage]
   (p-tau217 / Aβ Ratio Measurement)    (Amyloid Accumulation & Vascular Check)      (Lecanemab, Donanemab Precision Dosing)

① Early Screening: Blood-Based Liquid Biopsy

• p-Tau217 & Aβ(amyloid-beta)42/40 Blood Tests: Previously, amyloid accumulation could only be confirmed via expensive PET scans or cerebrospinal fluid (CSF) testing. Today, measuring trace amounts of p-Tau217 protein and amyloid-beta ratios in the blood enables simple screening of high-risk individuals even before entering the Mild Cognitive Impairment (MCI) stage.

② Novel Therapeutic Techniques: Anti-Amyloid Antibody Drugs

• Lecanemab & Donanemab: Disease-modifying therapies (DMTs) that directly remove amyloid-beta plaques already accumulated in the brain via immune mechanisms, slowing Alzheimer’s progression by over 20–30%.
• Customized Titration Strategy: To reduce side effects such as ARIA (Amyloid-Related Imaging Abnormalities: brain edema and microhemorrhages), precision dosing guidelines have been established to step up initial doses based on the patient’s genotype (APOE $\epsilon 4$ϵ4) and cerebrovascular condition.

③ Ultra-Fast MRI Monitoring System

• To safely monitor ARIA side effects occurring during treatment, Rapid MRI Protocols—reducing scan times from 20 minutes to around 6 minutes—have been introduced, eliminating diagnostic bottlenecks.

3. In-Depth Investment Analysis for Biomedical & Medical Devices

The aptamer sensor-coupled Organoid-on-a-chip developed by the SKKU team, along with the recent Alzheimer’s diagnostic and therapeutic ecosystem, holds immense commercial and technical value in the biomedical sector.

                           ┌── [Organoid-on-a-Chip] ──➔ Maximizing Clinical Success Rate & Reducing Drug R&D Costs
[Neurodegenerative Market]
                           └── [Blood Testing & Drugs] ──➔ Market Expansion from Ultra-Early Diagnosis to Therapeutics

① Investment Value and Commercial Feasibility of Parkinson’s Sensor Chips

The technology developed by the SKKU research team is an ultra-sensitive nanoplasmonic optical sensor capable of continuously measuring minute dopamine concentrations down to 8.3 pM (picomolar, 1-trillionth level) for 12 hours.

• Significantly Boosting Clinical Success Rates (R&D Cost Reduction): The largest hurdle in neurodegenerative drug development has been the wide gap between animal testing and human clinical trials (over 90% failure rate). Utilizing patient-derived stem-cell-based brain organoid chips allows pre-validation of candidate drug response rates, peak efficacy timing, and duration, shortening pharmaceutical R&D costs and timelines by years.
• Companion Diagnostics (CDx) & Precision Medical Devices: As individual patients require different optimal doses of drugs like L-DOPA, this chip extends beyond a drug-screening tool into a medical device platform for patient-specific dosing decisions. Establishing mass-production capabilities within four years is expected to attract pipeline orders from global biotech firms.

② Investment Points for Alzheimer’s In Vitro Diagnostics (IVD) & Integrated Medical Devices

• In Vitro Diagnostics (IVD) Biomarker Market: Blood-based Alzheimer’s diagnostic kits complement and replace expensive PET scans, penetrating primary care clinics to build a multi-billion-dollar consumer market.
• Ultra-Fast MRI & AI Image Analysis Chips: Since ARIA side-effect monitoring is essential during antibody drug administration, strong growth in the AI-driven ultra-fast MRI image analysis and precision brain imaging Software as a Medical Device (SaMD) market is guaranteed.

💡 Bottom Line for Investors and Industry Researchers

1. Academic & Medical Value: By clearly targeting the pathological differences between Parkinson’s disease (loss of dopamine-producing cells) and Alzheimer’s disease (accumulation of toxic proteins), precision medicine solutions—real-time dopamine monitoring for Parkinson’s and blood-based diagnosis paired with antibody protein clearance for Alzheimer’s—are firmly establishing themselves.
2. Biomedical Investment Value:
   • Drug Development Services (CRO/CDMO): Organoid-on-a-chip drug efficacy evaluation platforms are becoming indispensable tools for global pharma efficiency, offering high business scalability.
   • Diagnostic & Monitoring Medical Devices: Long-term investment remains solid across blood diagnostic kits, aptamer biosensor chips, and ultra-fast MRI AI solutions within an aging society’s early diagnosis and personalized dosing ecosystem.